Long-term efficacy and safety of fostemsavir among subgroups of heavily treatment-experienced adults with HIV-1

Long-term efficacy and safety of fostemsavir among subgroups of heavily treatment-experienced adults with HIV-1

The aim of this study was to understand how demographic and treatment-related factors impact responses to fostemsavir-based regimens. BRIGHTE is an ongoing phase 3 study evaluating twice-daily fostemsavir 600 mg and optimized background therapy (OBT) in heavily treatment-experienced individuals fail...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:AIDS 2021-06, Vol.35 (7), p.1061-1072
Hauptverfasser: Ackerman, Peter, Thompson, Melanie, Molina, Jean-Michel, Aberg, Judith, Cassetti, Isabel, Kozal, Michael, Castagna, Antonella, Martins, Marcelo, Ramgopal, Moti, Sprinz, Eduardo, Treviño-Pérez, Sandra, Streinu-Cercel, Adrian, Latiff, Gulam H., Pialoux, Gilles, Kumar, Princy N., Wang, Marcia, Chabria, Shiven, Pierce, Amy, Llamoso, Cyril, Lataillade, Max
Format: Artikel
Sprache:eng
Schlagworte:
Adult
Anti-HIV Agents - therapeutic use
CD4 Lymphocyte Count
Clinical Science
HIV Infections - drug therapy
HIV-1
Human health and pathology
Humans
Life Sciences
Organophosphates
Piperazines
Treatment Outcome
Viral Load
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:The aim of this study was to understand how demographic and treatment-related factors impact responses to fostemsavir-based regimens. BRIGHTE is an ongoing phase 3 study evaluating twice-daily fostemsavir 600 mg and optimized background therapy (OBT) in heavily treatment-experienced individuals failing antiretroviral therapy with limited treatment options (Randomized Cohort 1-2 and Nonrandomized Cohort 0 fully active antiretroviral classes). Virologic response rates (HIV-1 RNA
ISSN:0269-9370
1473-5571
DOI:10.1097/QAD.0000000000002851